Literature DB >> 26458921

Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.

Eleonora Scaioli1, Antonio Colecchia2, Giovanni Marasco3, Ramona Schiumerini4, Davide Festi5.   

Abstract

Colonic diverticulosis imposes a significant burden on industrialized societies. The current accepted causes of diverticula formation include low fiber content in the western diet with decreased intestinal content and size of the lumen, leading to the transmission of muscular contraction pressure to the wall of the colon, inducing the formation of diverticula usually at the weakest point of the wall where penetration of the blood vessels occurs. Approximately 20 % of the patients with colonic diverticulosis develop abdominal symptoms (i.e., abdominal pain and discomfort, bloating, constipation, and diarrhea), a condition which is defined as symptomatic uncomplicated diverticular disease (SUDD). The pathogenesis of SUDD symptoms remains uncertain and even less is known about how to adequately manage bowel symptoms. Recently, low-grade inflammation, altered intestinal microbiota, visceral hypersensitivity, and abnormal colonic motility have been identified as factors leading to symptom development, thus changing and improving the therapeutic approach. In this review, a comprehensive search of the literature regarding on SUDD pathogenetic hypotheses and pharmacological strategies was carried out. The pathogenesis of SUDD, although not completely clarified, seems to be related to an interaction between colonic microbiota alterations, and immune, enteric nerve, and muscular system dysfunction (Cuomo et al. in United Eur Gastroenterol J 2:413-442, 2014). Greater understanding of the inflammatory pathways and gut microbiota composition in subjects affected by SUDD has increased therapeutic options, including the use of gut-directed antibiotics, mesalazine, and probiotics (Bianchi et al. in Aliment Pharmacol Ther 33:902-910, 2011; Comparato et al. in Dig Dis Sci 52:2934-2941, 2007; Tursi et al. in Aliment Pharmacol Ther 38:741-751, 2013); however, more research is necessary to validate the safety, effectiveness, and cost-effectiveness of these interventions.

Entities:  

Keywords:  Diverticular disease; Gut microbiota; Low-grade inflammation; Mesalazine; Probiotics

Mesh:

Substances:

Year:  2015        PMID: 26458921     DOI: 10.1007/s10620-015-3925-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  91 in total

1.  Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology.

Authors:  N H Stollman; J B Raskin
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

Review 2.  Toll-like receptor signaling.

Authors:  Shizuo Akira
Journal:  J Biol Chem       Date:  2003-07-30       Impact factor: 5.157

Review 3.  New physiopathological and therapeutic approaches to diverticular disease: an update.

Authors:  Antonio Tursi
Journal:  Expert Opin Pharmacother       Date:  2014-03-31       Impact factor: 3.889

4.  Efficacy of mesalazine in the treatment of symptomatic diverticular disease.

Authors:  Francesco Di Mario; Giovanni Aragona; Gioacchino Leandro; Giuseppe Comparato; Libera Fanigliulo; Lucas G Cavallaro; Giulia M Cavestro; Veronica Iori; Marta Maino; Alì M Moussa; Alessandro Gnocchi; Giancarlo Mazzocchi; Angelo Franzé
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

5.  High fibre diet in symptomatic diverticular disease of the colon.

Authors:  A L Leahy; R M Ellis; D S Quill; A L Peel
Journal:  Ann R Coll Surg Engl       Date:  1985-05       Impact factor: 1.891

6.  Diet and the faecal microflora of infants, children and adults in rural Nigeria and urban U.K.

Authors:  A M Tomkins; A K Bradley; S Oswald; B S Drasar
Journal:  J Hyg (Lond)       Date:  1981-06

7.  The changing trend of diverticular disease in a developing nation.

Authors:  S S Fong; E Y Tan; A Foo; R Sim; D M O Cheong
Journal:  Colorectal Dis       Date:  2011-03       Impact factor: 3.788

8.  Assessment and grading of mucosal inflammation in colonic diverticular disease.

Authors:  Antonio Tursi; Giovanni Brandimarte; Walter Elisei; Gian Marco Giorgetti; Cosimo Damiano Inchingolo; Silvio Danese; Fabio Aiello
Journal:  J Clin Gastroenterol       Date:  2008-07       Impact factor: 3.062

9.  Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial.

Authors:  M H Ornstein; E R Littlewood; I M Baird; J Fowler; W R North; A G Cox
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

10.  Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians.

Authors:  Francesca L Crowe; Paul N Appleby; Naomi E Allen; Timothy J Key
Journal:  BMJ       Date:  2011-07-19
View more
  4 in total

Review 1.  Epidemiology and Pathophysiology of Diverticular Disease.

Authors:  Semeret T Munie; Surya P M Nalamati
Journal:  Clin Colon Rectal Surg       Date:  2018-06-22

Review 2.  Animal Models of Diverticulosis: Review and Recommendations.

Authors:  Bhavesh Patel; Xiaomei Guo; Jillian Noblet; Sean Chambers; Ghassan S Kassab
Journal:  Dig Dis Sci       Date:  2018-04-20       Impact factor: 3.199

3.  Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy.

Authors:  Antonio De Vincentis; Marco Santonico; Federica Del Chierico; Annamaria Altomare; Benedetta Marigliano; Alice Laudisio; Sofia Reddel; Simone Grasso; Alessandro Zompanti; Giorgio Pennazza; Lorenza Putignani; Michele Pier Luca Guarino; Michele Cicala; Raffaele Antonelli Incalzi
Journal:  Front Med (Lausanne)       Date:  2021-07-19

Review 4.  Lactobacillus paracasei CNCM I 1572: A Promising Candidate for Management of Colonic Diverticular Disease.

Authors:  Elisabetta Bretto; Ferdinando D'Amico; Walter Fiore; Antonio Tursi; Silvio Danese
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.